AXIM Biotechnologies (AXIM) Stock Overview
Develops diagnostic healthcare solutions for ophthalmological conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AXIM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AXIM Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.006 |
| 52 Week High | US$0.019 |
| 52 Week Low | US$0.0013 |
| Beta | 0.095 |
| 1 Month Change | -9.85% |
| 3 Month Change | 98.33% |
| 1 Year Change | -20.67% |
| 3 Year Change | -91.08% |
| 5 Year Change | -98.08% |
| Change since IPO | -90.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXIM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.8% | -2.3% | 0.0005% |
| 1Y | -20.7% | -11.7% | 10.0% |
Return vs Industry: AXIM underperformed the US Biotechs industry which returned -11% over the past year.
Return vs Market: AXIM underperformed the US Market which returned 10.4% over the past year.
Price Volatility
| AXIM volatility | |
|---|---|
| AXIM Average Weekly Movement | 22.8% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: AXIM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AXIM's weekly volatility has decreased from 31% to 23% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 7 | Catalina Valencia | www.aximbiotech.com |
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin ADDE test. It also operates a full-service center for custom biomarker and biopharmaceutical research, custom assay development, clinical sample testing, and precision data delivery.
AXIM Biotechnologies, Inc. Fundamentals Summary
| AXIM fundamental statistics | |
|---|---|
| Market cap | US$2.37m |
| Earnings (TTM) | -US$4.14m |
| Revenue (TTM) | US$92.90k |
Is AXIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXIM income statement (TTM) | |
|---|---|
| Revenue | US$92.90k |
| Cost of Revenue | US$1.74k |
| Gross Profit | US$91.15k |
| Other Expenses | US$4.23m |
| Earnings | -US$4.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 98.12% |
| Net Profit Margin | -4,452.06% |
| Debt/Equity Ratio | -69.2% |
How did AXIM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/20 14:00 |
| End of Day Share Price | 2025/06/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AXIM Biotechnologies, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.